AZN catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
Windows longer than 90 days are part of TrialScanner, so this list covers the next 90 days.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 24, 2026Sponsor estimate | NCT06267729Study of AZD0754 in Participants With Metastatic Prostate CancerAstraZeneca · Metastatic Prostate Cancer | AZNLead | Phase 1/Phase 2 | Recruiting | Locked | Locked | Locked |
| Nov 29, 2026Sponsor estimate | NCT06376097Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service.AstraZeneca · Lung Cancer | AZNLead | No phase registered | Recruiting | Locked | Locked | Locked |
| Nov 30, 2026Sponsor estimate | NCT07361276Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care SystemAstraZeneca · Hypertension | AZNLead | No phase registered | Recruiting | Locked | Locked | Locked |
- Primary completion Nov 24, 2026Sponsor estimatePhase 1/Phase 2NCT06267729Study of AZD0754 in Participants With Metastatic Prostate CancerAstraZeneca · Metastatic Prostate CancerRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 29, 2026Sponsor estimateNo phase registeredNCT06376097Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service.AstraZeneca · Lung CancerRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT07361276Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care SystemAstraZeneca · HypertensionRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 8, 2026Sponsor estimatePhase 1NCT07290283A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy ParticipantsAstraZeneca · Healthy ParticipantsRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 3NCT06607627PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia GravisAlexion Pharmaceuticals, Inc. · Generalized Myasthenia GravisRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT06491862RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in...AstraZeneca · Non-squamous Non-Small Cell Lung CancerRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT06548152AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON DatabaseAstraZeneca · Chronic Lymphocytic LeukemiaRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT06713369AZD5305 hADME in Patients With Advanced Solid MalignanciesAstraZeneca · Locally Advanced or Metastatic Solid TumorRecruitingAZNLeadFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT07038928TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian FederationAstraZeneca · Bladder CancerRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT07404202A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor PatientsAstraZeneca · Pan-tumor(NSCLC, GYN Cancers, BTC and UC)RecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT07593196HER2-positive Metastatic Breast Cancer in KazakhstanAstraZeneca · Metastatic Breast CancerRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 29, 2027Sponsor estimate | NCT07024823A Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes...AstraZeneca · Chronic Kidney Disease | AZNLead | Phase 1 | Recruiting | Locked | Locked | Locked |
| Jan 31, 2027Sponsor estimate | NCT07065344A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of...AstraZeneca · Hematology | AZNLead | No phase registered | Recruiting | Locked | Locked | Locked |
- Primary completion Jan 29, 2027Sponsor estimatePhase 1NCT07024823A Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes...AstraZeneca · Chronic Kidney DiseaseRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimateNo phase registeredNCT07065344A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of...AstraZeneca · HematologyRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 4, 2027Sponsor estimate | NCT07546760A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234AstraZeneca · Hepatic Impairment | AZNLead | Phase 1 | Recruiting | Locked | Locked | Locked |
| Feb 11, 2027Sponsor estimate | NCT07215702A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.AstraZeneca · Sepsis | AZNLead | Phase 2 | Recruiting | Locked | Locked | Locked |
- Primary completion Feb 4, 2027Sponsor estimatePhase 1NCT07546760A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234AstraZeneca · Hepatic ImpairmentRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 11, 2027Sponsor estimatePhase 2NCT07215702A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.AstraZeneca · SepsisRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 15 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.